Overtraining syndrome Not Applicable
Conditions
Interventions
A preliminary analysis of the candidates was done by email correspondence, and included questions regarding age, sex, and approximate body weight and height. Based on the candidate’s responses, their
Sponsors
Federal University of São Paulo
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: All participants: 1. Male 2. Aged between 18 and 50 years 3. BMI between 20.0 and 32.9 kg/m2 4. Absence of previous psychiatric disorders and use of centrally-acting drugs 5. Absence of any hormonal therapy in the previous six months Healthy elite athletes (ATL): The following additional inclusion criteria regarding training aspects were required from all ATL regarding training level: 1. Exercise at least four times a week, for a total of >300 min a week 2. Moderate-to-vigorous training intensity (self-perception comparing own training with that of others, based on the Talk Test) 3. Continuous training for the current sport(s) for at least six months, without interruption for >30 days Non-physically active control subjects (NPAC) were required to: 1. Fulfill the initial inclusion criteria 2. Be sedentary (without any physical activity, including light exercises) for at least three years 3. No history of exercise that would fulfill the criteria for ATL
Exclusion criteria
Exclusion criteria: Does not meet the inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EROS-HPA axis: 1. ACTH and cortisol measured using commercially available electrochemiluminescence assay: basal, during hypoglycemia, 30 min after hypoglycemia, and during an insulin tolerance test (ITT) on Day 2 (48h) 2. Cortisol response to a cosyntropin stimulation test (CST) measured using commercially available electrochemiluminescence assay at 30 min and 60 min after injection on Day 1 (24h) 3. Salivary cortisol rhythm (SCR): salivary cortisol measured using commercially available electrochemiluminescence assay at awakening, 30 min after, at 4PM, at 11PM, cortisol awakening response (CAR), on Day 0 (baseline) EROS-STRESS: 1. GH and prolactin measured using commercially available electrochemiluminescence assay: basal, during hypoglycemia, 30 min after hypoglycemia, prolactin increase during ITT, on Day 2 (48h) 2. Glucose behaviour during an ITT: serum glucose measured using enzymatic assay of hexokinase, basal and during hypoglycemia, adrenergic symptoms during hypoglycemia (0-10), neuroglycopenic symptoms during hypoglycemia (0-10), on Day 2 (48h) EROS-BASAL: 1. Hormonal markers measured on Day 1 (24h): 1.1. Total testosterone measured using chemiluminescence assay 1.2. Estradiol measured using chemiluminescence assay 1.3. IGF-1 measured using chemiluminescence assay 1.4. TSH measured using chemiluminescence assay 1.5. Free T3 measured using chemiluminescence assay 1.6. Total catecholamines measured using calorimetric enzymatic assays 1.7. Metanephrines measured using calorimetric enzymatic assays 1.8. Noradrenaline measured using calorimetric enzymatic assays 1.9. Epinephrine measured using calorimetric enzymatic assays 1.10. Dopamine measured using calorimetric enzymatic as | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Brazil
Outcome results
None listed